The benefit of consolidation radiotherapy to initial disease bulk in XXXX with advanced @entity978 who achieved complete remission after standard chemotherapy.

@entity1 @entity66 @entity138 @entity5 @entity978 @entity1349
BACKGROUND/PURPOSE: The aim of this study was to evaluate the role of consolidation radiotherapy ( @entity138 ) in advanced-stage @entity978 ( @entity978 ) with initial bulky sites after radiological complete remission (CR) or partial response (PR) with positron emission tomography-negative (metabolic CR) following standard chemotherapy (ABVD [Adriamycin, bleomycin, vinblastine, and dacarbazine]) six to eight cycles. @entity1 AND METHODS: Adult @entity1 with @entity978 treated at our institute during the period 2006 to 2012 were retrospectively evaluated. One hundred and ninety-two @entity1 with @entity66 size (>7 cm) who attained radiological CR/PR and metabolic CR were included in the analysis. One hundred and thirteen @entity1 who received radiotherapy ( @entity138 ) as consolidation postchemotherapy ( @entity138 group) were compared to 79 @entity1 who did not receive @entity138 ( @entity138 ). Disease-free (DFS) and @entity1349 ( @entity1349 ) rates were estimated using the Kaplan-Meier method and were compared according to treatment group by the log-rank tests at P  <=0.05 significance level. RESULTS: The mean age of the cohort was 33 (range: 14 to 81) years. Eighty-four @entity1 received involved-field radiation and 29 @entity1 received involved-site @entity138 . The @entity138 group had worse prognostic factors compared to the @entity138 . Thirteen (12%) relapses occurred in the @entity138 group, and 19 (24%) relapses occurred in the @entity138 . Nine @entity1 (8%) in the @entity138 group died, compared to eleven @entity1 (14%) in the @entity138 . Second @entity5 were seen in only five @entity1 : three @entity1 in the @entity138 group compared to two @entity1 in the @entity138 . At 5 years, overall DFS was 79%  9% and @entity1349 was 85%  9%. There was significant statistical difference between the @entity138 group and the @entity138 regarding 5-year DFS: 86%  7% and 74%  9%, respectively (P  <=0.02). However, the 5-year @entity1349 was 90%  5% for the @entity138 group and 83%  8% for the @entity138 , with no statistical difference (P  <=0.3). CONCLUSION: The results of our study suggest that consolidation @entity138 in @entity1 with @entity978 with @entity66 who had postchemotherapy radiologic CR or PR with metabolic CR improved the DFS.
